Home › NDC Lookup › RxCUI directory › RxCUI 847230

3 ML insulin glargine 100 UNT/ML Pen Injector — RxCUI 847230

RxNorm drug concept · Semantic clinical drug
RxCUI 847230 Semantic clinical drug · SCD ● Current RxNorm concept 7 FDA products 10 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI847230
Official name3 ML insulin glargine 100 UNT/ML Pen Injector
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asinsulin analog, glargine 300 UNT Pen Injector; insulin glargine 100 UNT/ML in 3 ML Pen Injector; 3 ML insulin analog, glargine 100 UNT/ML Pen Injector; insulin glargine 300 UNT per 3 ML Pen Injector
FDA products mapped7
Package NDCs mapped10
Reported Medicaid activity (SDUD)3,224,614 prescriptions · 52 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Insulin Glargine (rDNA origin) Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Insulin glargine is a long-acting insulin that works as a steady background insulin for your body throughout the day. It helps move sugar from your bloodstream into your cells for...
  • What exactly does insulin glargine do, and why do I need it?
  • You inject insulin glargine once a day, under the skin (not into a vein or muscle), in your abdomen, thigh, or upper arm. The key is to pick the same time every day and stick to it...
  • Low blood sugar — called hypoglycemia — is the most common and most serious risk. Signs include shakiness, sweating, dizziness, confusion, rapid heartbeat, or sudden hunger. Mild c...
📖 Read our full Insulin Glargine (rDNA origin) Injection guide →

🕸️ Concept Web — How 3 ML insulin glargine 100 UNT/ML Pen Injector Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 3 ML insulin glargine 100 UNT/ML Pen Injector RxCUI 847230

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Insulin glargine 274783
  2. Brand names 2

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Basaglar 1736859
    • Lantus 261551
  3. Dose forms 8

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Insulin glargine Pen Injector 1653497
    • Insulin glargine Injectable Product 1157459
    • Insulin glargine Pen Injector [Basaglar] 1736861
    • Insulin glargine Pen Injector [Lantus] 1653499
    • Basaglar Injectable Product 1736862
    • Lantus Injectable Product 1175624
    • Pen Injector 1649571
    • Injectable Product 1151126
  4. Clinical & branded drugs 5

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 16 of 16 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Insulin glargine 100 UNT/ML SCDC · 343226
  • Insulin glargine Pen Injector SCDF · 1653497
  • Insulin glargine Injectable Product SCDG · 1157459

Brand-Name Concepts

📦 FDA Products & Package NDCs

7 products · 10 package NDCs
10 package NDCs map to RxCUI 847230 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00002-7715-59 5 SYRINGE in 1 CARTON (0002-7715-59) / 3 mL in 1 SYRINGE (0... BASAGLAR KwikPen Eli Lilly and Company 2016-06-17
00002-7715-63 1 SYRINGE in 1 CARTON (0002-7715-63) / 3 mL in 1 SYRINGE BASAGLAR KwikPen Eli Lilly and Company 2016-07-15
00002-8214-05 5 SYRINGE in 1 CARTON (0002-8214-05) / 3 mL in 1 SYRINGE (0... BASAGLAR Tempo Pen Eli Lilly and Company 2019-11-15
00088-2219-00 1 SYRINGE in 1 CARTON (0088-2219-00) / 3 mL in 1 SYRINGE Lantus Solostar sanofi-aventis U.S. LLC 2009-09-23
00088-2219-05 5 SYRINGE in 1 CARTON (0088-2219-05) / 3 mL in 1 SYRINGE (0... Lantus Solostar sanofi-aventis U.S. LLC 2009-09-23
00088-2220-33 1 VIAL, GLASS in 1 CARTON (0088-2220-33) / 10 mL in 1 VIAL,... Lantus sanofi-aventis U.S. LLC 2009-09-23
00088-2220-34 1 VIAL, GLASS in 1 CARTON (0088-2220-34) / 10 mL in 1 VIAL,... Lantus sanofi-aventis U.S. LLC 2009-09-23
50090-1398-00 5 SYRINGE in 1 PACKAGE (50090-1398-0) / 3 mL in 1 SYRINGE Lantus Solostar A-S Medication Solutions 2014-11-28
50090-4068-00 5 SYRINGE in 1 CARTON (50090-4068-0) / 3 mL in 1 SYRINGE LANTUS SOLOSTAR A-S Medication Solutions 2019-01-17
50090-6178-00 5 SYRINGE in 1 CARTON (50090-6178-0) / 3 mL in 1 SYRINGE Insulin Glargine Solostar A-S Medication Solutions 2022-10-19
Observed labelers: sanofi-aventis U.S. LLC (4) · A-S Medication Solutions (3) · Eli Lilly and Company (3) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ml · median
$13.5477
Range $6.1513–$20.9549 · middle 50% $6.1625–$20.9356 · 4 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.